Global Expansion of LAMP Products
First written in FY2016. 12 of 22 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- 2026-07-30AdvancedResults presentation
「Genetics-related products: TB-LAMP tuberculosis testing reagent sales for Africa increased」
Higher sales of TB-LAMP for Africa were identified as a factor behind higher first-quarter revenue. - FY2026AdvancedAnnual report
「The Loopamp MTBC Detection Kit and two other products obtained WHO Prequalification (WHO-PQ) certification for in vitro diagnostic products from the World Health Organization (WHO) in December 2025 and were listed on the Prequalified In Vitro Diagnostic Products list.」
Three tuberculosis testing products related to LAMP-based testing obtained WHO-PQ certification and were listed on an international product list. Three malaria products also obtained domestic approval and were launched. - FY2025AdvancedAnnual report
「The LAMP-based tuberculosis testing system TB-LAMP was adopted on a large scale in the Federal Republic of Nigeria in 2023 as an active tuberculosis case-finding program through mobile screening. This initiative continued and expanded in fiscal 2024, contributing to tuberculosis eradication efforts locally.」
The large-scale adoption of TB-LAMP in Nigeria continued and expanded in fiscal 2024. The new medium-term management plan also explicitly provides for expansion into India and African countries. - FY2023AdvancedAnnual report
「In LAMP-related products, we launched the IVDR-compliant Loopamp PURE DNA Extraction Kit in July 2022.」
The launch of an IVDR-compliant product was reported as a new regulatory and product rollout for LAMP-based products. - FY2022RestatedAnnual report
「We will expand our product lineup to address threatening infectious diseases and roll out genetic testing systems for tuberculosis, malaria and other diseases globally.」
The policy of globally rolling out genetic testing systems for tuberculosis, malaria and other diseases has been carried forward into the infectious disease segment of the EIKEN ROAD MAP 2030. - FY2021AdvancedAnnual report
「In genetic testing, we began rolling out LAMP-based novel coronavirus detection reagents in India, Central Asia and Europe. In addition, tuberculosis complex genetic testing reagents were included in guidelines in high-burden countries and selected by the Global Fund, and we will work to promote and establish the use of testing.」
The rollout of LAMP-based novel coronavirus detection reagents began in multiple regions, while tuberculosis complex testing reagents were included in guidelines in high-burden countries and selected by the Global Fund. - FY2020AdvancedAnnual report
「In genetic testing, we conducted demonstration tests mainly in Africa and Asia toward the global rollout of LAMP-based tuberculosis complex and malaria genetic testing reagents, and announced our activity policy at the 7th Tokyo International Conference on African Development (TICAD7).」
The reported activities progressed from Field Studies and clinical trials in Africa and Asia to demonstration testing, and an activity policy was announced at TICAD7. - FY2019AdvancedAnnual report
「In genetic testing, we conducted clinical trials mainly in Asia and Africa toward the global rollout of LAMP-based tuberculosis complex and malaria genetic testing reagents. Using the adoption case in Cameroon as a model, we are working to replicate the approach in other countries.」
For LAMP-based tuberculosis and malaria testing reagents, the project advanced from clinical trials in Asia and Africa to the stage of replicating the Cameroon adoption case in other countries. - FY2019-Q3RestatedAnnual report
「Other products, including medical devices and genetic testing products, generated ¥3,135 million in sales, down 11.7% year on year, as higher sales of LAMP-based genetic testing reagents were offset by lower sales of urine testing equipment for overseas markets and other products.」
Although higher sales of LAMP-based reagents were reported, no new milestone in the global rollout, such as a new overseas sales agreement or adoption under a relevant system, was indicated. - FY2019-Q2RestatedAnnual report
「Other products, including medical devices and genetic testing products, generated ¥1,977 million in sales, down 15.1% year on year, as higher sales of LAMP-based genetic testing reagents were offset by lower sales of urine testing equipment for overseas markets and other products.」
Although higher sales of LAMP-based reagents were reported, no new milestone in the global rollout, such as a new overseas sales agreement or adoption under a relevant system, was indicated. - FY2018RestatedAnnual report
「For genetic testing reagents, we conducted Field Studies mainly in Asia and Africa toward the global rollout of LAMP-based tuberculosis complex and malaria genetic testing reagents. The tuberculosis complex genetic testing reagent was also listed in the GDF (Global Drug Facility) catalogue.」
The previously reported stage of conducting Field Studies in Asia and Africa and being listed in the GDF catalogue continues. - FY2018-Q3AdvancedAnnual report
「We conducted Field Studies mainly in Africa and Asia toward the global rollout of LAMP-based tuberculosis and malaria genetic testing reagents. The TB-LAMP product for tuberculosis genetic testing was also listed in the GDF (Global Drug Facility※) catalogue.」
In addition to continuing Field Studies in Africa and Asia, the TB-LAMP product was listed in the GDF catalogue, adding a distribution channel. - FY2018-Q2RestatedAnnual report
「We conducted Field Studies mainly in Africa and Asia toward the global rollout of LAMP-based tuberculosis and malaria genetic testing reagents.」
Field Studies on LAMP-based tuberculosis and malaria genetic testing reagents are continuing, mainly in Africa and Asia. - FY2018-Q1AdvancedAnnual report
「We also conducted Field Studies mainly in Africa and Asia toward the global rollout of LAMP-based tuberculosis and malaria genetic testing reagents.」
For LAMP-based tuberculosis and malaria genetic testing reagents, the project advanced to the stage of conducting Field Studies mainly in Africa and Asia. - FY2017AdvancedAnnual report
「The LAMP-based tuberculosis genetic testing method developed jointly with FIND (Foundation for Innovative New Diagnostics) received a WHO recommendation, and POLICY GUIDANCE was issued. We also entered into a global sales agreement with Germany's HUMAN Gesellschaft fuer Biochemica und Diagnostica mbH for tuberculosis and malaria genetic testing reagents and began sales. In February 2017, our proposed project to promote the adoption of mass colorectal cancer screening in Thailand was selected under JICA's Private-Sector Technology Promotion Project by the Japan International Cooperation Agency (JICA).」
In addition to the issuance of POLICY GUIDANCE following the WHO recommendation and the start of sales with HUMAN, the selection of the Thailand project by JICA was reported as progress. - FY2017-Q3RestatedAnnual report
「The LAMP-based tuberculosis genetic testing method developed jointly with FIND (Foundation for Innovative New Diagnostics) received a WHO recommendation, and POLICY GUIDANCE was issued. We also entered into a global sales agreement with Germany's HUMAN Gesellschaft fuer Biochemica und Diagnostica mbH for tuberculosis and malaria genetic testing reagents.」
The WHO recommendation, issuance of POLICY GUIDANCE and sales agreement with HUMAN are still cited as progress in the global rollout. No new agreements or other additions have been reported. - FY2017-Q2AdvancedAnnual report
「The LAMP-based tuberculosis genetic testing method developed jointly with FIND (Foundation for Innovative New Diagnostics) received a WHO recommendation, and POLICY GUIDANCE was issued. We also entered into an overseas sales agreement with Germany's HUMAN Gesellschaft fuer Biochemica und Diagnostica mbH for tuberculosis and malaria genetic testing reagents.」
The LAMP-based tuberculosis genetic testing method received a WHO recommendation and POLICY GUIDANCE was issued, followed by an overseas sales agreement for tuberculosis and malaria genetic testing reagents. - FY2017-Q1RestatedAnnual report
「We will promote the global rollout of tuberculosis complex detection reagents using the LAMP method that we are developing jointly with FIND (Foundation for Innovative New Diagnostics).」
Continuing to promote the global rollout of LAMP-based tuberculosis complex detection reagents developed jointly with FIND. - FY2016First statedAnnual report
「The Loopamp Mycobacterium tuberculosis Complex Detection Kit and Loopamp PURE DNA Extraction Kit, developed jointly with FIND as tuberculosis detection reagents for developing countries, have already been launched in Japan. To obtain WHO recommendations for global rollout, we submitted additional evaluation test data from 14 countries to WHO.」
Additional evaluation test data from 14 countries were submitted to obtain WHO recommendations.